ACHC accreditation as a symbol of excellence and allow our patients, insurance providers and taxpayers know that BioPlus with the highest level of commitment to quality and accountability, said Alvin Montanez, Pharm.D, senior vice president BioPlus.

ACHC Accreditation recently, adding to the growing list of qualifications that BioPlus, which is achieved by including URAC, VIPPS and Chapter (Community Health Accreditation Program). These qualifications demonstrate commitment to excellence in service and results BioPlus patients. Is proud to confirm that the other bodies, ACHC, shows that BioPlus as a measure of our performance in managing patient care and services, doctors Montanez added:

Song BioPlus as other indicators of quality, acceptance of patients to treat their specific pharmacy. Recent statistics from the sample program in BioPlus treatment, which includes more than 22 200 patients BioPlus for hepatitis C, cancer, rheumatoid arthritis, psoriasis, Crohns disease and other health conditions, showed that 91 percent of the unloading compliance BioPlus. In comparison, the compliance rate for retail pharmacy and mail order only 50 percent.

ACHC, a nonprofit organization founded in 1986, one of a small number of specialized agencies for the pharmaceutical industry is leading branch. Program approved by the supplier for the supplier to describe the criteria that best represents the quality of care and patient safety.

BioPlus

owned pharmacies, URAC accredited, national specialized pharmacy services and infusion of high touch pharmacy specifically for patients with chronic diseases such as hepatitis, bleeding disorders, cancer, and other conditions. BioPlus licensed in all 50 states, UN specialized largest independent pharmacy. Approved VIPPS, Accreditation Commission for Healthcare (ACHC) and the Community Health Accreditation Program (Chapter), patients can call 1-888-514-8082 toll-free pharmacy

Information: http://www.bioplusrx.com
Contact
: info (at) bioplusrx (dot) com

Phone: 1-800-566-6103

# # # # #

Peter Chu, PhD, lead program we

as therapeutic antibodies targeting cancer stem cells and other colon cancer Clevers Kipps doctor’s clinic and the doctor will advance with the views of scientific and clinical value is provided, said shock therapy, the president and founder. “Doctor of the world’s leading experts in stem cell biology Clevers in the colon and play an important role in guiding the development of a unique shock therapy that targets high-value, doctor of colon cancer stem cells credibility novel Kipps receptors. Clinical oncologist is known that in-depth knowledge and experience in translation of bench to bedside in the cancer drug drug program will help promote the clinic is blocked

Hans Clevers, doctors, PhD, director of Hubrecht Laboratory, Netherlands Institute for Biology in Utrecht, Netherlands. More than twenty years ago, doctors Clevers research tool that shows the process of normal intestinal stem cells and cancer stem cells in colon cancer has become. He is one of the leading experts on the route Wnt-catenin signaling is nuclear. Clevers doctors working in several leading journals, including 31 articles in the cell alone, science and nature have been published. Clevers doctor doctorate in education from Harvard, the combined fund Farbr Cancer Institute has been committed. He is a member of the Royal Netherlands Academy of Sciences since 2000 has been the recipient of many awards including the prestigious Spinoza Award in 2001, the Louis Jeantet Prize in 2004, Memorial Sloan-Kettering’s name, Catherine Berkan Judd Award in 2005, Rabbi Shai Shacknai kolff Award Award in 2006 and 2011. Clevers also founded several biotechnology companies, doctors pharmacy Semaia was obtained by Hybrigenics SA. He is currently negotiating with the board of directors of the venture capital firm Life Sciences Partners BV and BV Aglaia medical participation

I was honored as a founder member of the Advisory Committee.

Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research and interim director of Moores Cancer Center at the University of California, San Diego. Kipps received doctor M.D. And a doctoral degree with high honors from Harvard University Magna Fellowship at Stanford University and residency training will be done. He has extensive experience in drug discovery and development, consumer and commercial products from concept to clinical trials. In addition to translation of bench research scientists, doctors Kipps also a large number of clinical trials sponsored by industry or cancer registration, run a variety of institutional research consortium supported by the NIH-CLL, and two NIH MERIT Award. He has also led to the stem cell cancer antibody program budget $ 20M grant from the California Institute of Regenerative Medicine.

about the treatment of cramps, Inc.

Shock treatment, Inc. (Eclipse), a private biotechnology company dedicated to discovering and developing treatments that target stem cells, cancer and other forms of innovative cancer treatments. A subset of cancer stem cells in the tumor cells began to play an important role in tumor recurrence and metastasis. They are also involved in resistance to the current standard of care in cancer treatment. Eclipse-depth expertise in cancer stem cell biology and therapeutic antibodies for the development of new therapies for unmet needs in the care of cancer patients. For more information, please http://www.eclipsetherapeutics.com

# # # # #

href Href=”http://www.thedeadlyvixens.com/category/treatments-of-colon-cancer”> colon cancer treated with press releases